The Committee discusses Roche’s Genentech supplemental Biologics License Application (sBLA) 761121/S-008, for POLIVY (polatuzumab vedotin-piiq) for injection. The proposed use for this product is in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone for treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in a virtual meeting to be held on March 9 at 12 pm. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RHHBY:
- FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
- FDA Oncologic Drugs Advisory Committee to hold a virtual meeting
- Roche announces FDA approval of VENTANA PD-L1 Assay
- Roche expands collaboration with CDC to strengthen laboratory capabilities
- Societe Generale upgrades Roche to Buy, says ‘enough is enough’